Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
OM filed a Rule 144 notice for a small planned stock sale. The filing covers the proposed sale of 108 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on or about 01/07/2026, with the shares listed for trading on NASDAQ. The aggregate market value of this planned sale is reported as $461.16, based on market prices at the time of the notice.
The seller acquired the stock on 01/06/2026 through settlement of 289 vested performance stock units from the issuer as equity compensation for services rendered. Over the prior three months, the same seller disposed of 247 common shares on 11/17/2025 for gross proceeds of $1,136.20. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about OM’s current or prospective operations.
OM insider Leslie Trigg filed a notice of proposed sale of common stock under Rule 144. The filing covers the planned sale of 1,795 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $7,664.65 and 18,153,090 shares of common stock shown as outstanding.
The shares to be sold are part of a larger 4,904-share grant of common stock acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The filing also notes that Trigg previously sold 916 shares of common stock on 11/17/2025 for gross proceeds of $4,213.60. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
OM insider John Brottem filed a Rule 144 notice to sell 224 shares of common stock through Morgan Stanley Smith Barney LLC on approximately 01/07/2026, with an aggregate market value of $956.48 on the NASDAQ exchange. The filing notes that 18,153,090 shares of common stock were outstanding.
The shares to be sold come from 447 common shares acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The notice also reports that Brottem previously sold 388 shares of common stock on 11/17/2025 for gross proceeds of $1,784.80, and includes a representation that he is not aware of undisclosed material adverse information about OM.
Outset Medical, Inc. (OM)
Outset Medical, Inc. (OM) reported an insider share sale by its EVP Operations R&D & Service, Marc Nash. On 11/17/2025, Nash sold 247 shares of common stock at $4.60 per share in a transaction coded "S," leaving him with 48,268 shares beneficially owned. The company explains that the shares were sold solely to cover tax withholding obligations tied to the vesting of 674 shares of common stock underlying RSUs granted on March 15, 2023, July 24, 2023, and January 12, 2024, and that the sale did not represent a discretionary trade by Nash.
Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.
Outset Medical (OM) reported Q3 2025 results showing modest top-line growth and narrower losses. Revenue was $29.4 million, up slightly from $28.7 million a year ago, with product revenue of $20.6 million and service and other revenue of $8.9 million. Gross profit rose to $11.6 million as operating expenses declined, reducing the operating loss to $15.8 million. Net loss was $17.8 million, or $1.00 per share.
For the first nine months of 2025, revenue reached $90.6 million versus $84.2 million in 2024, and net loss improved to $62.2 million from $102.3 million. Cash, cash equivalents, restricted cash and short‑term investments totaled $182.0 million as of September 30, 2025. The company executed a 15‑for‑1 reverse stock split in March 2025 and completed financing steps earlier in the year, including issuing Series A convertible preferred stock that largely converted into 14,046,000 common shares at $12.00 per share and entering a $125 million term loan facility (with $100 million funded). As of November 6, 2025, shares outstanding were 18,153,090.
Outset Medical (OM)
The company notes the information is furnished under Item 2.02 and not deemed filed. The report includes forward‑looking statements and points readers to SEC filings for risk factors. Exhibit 99.1 contains the press release titled “Outset Medical Reports Third-Quarter Results.”
Marc Nash, Outset Medical's EVP, Research & Development, Operations and Services, received a grant of 5,617 restricted stock units (RSUs) on 08/25/2025. Each RSU converts to one share of common stock at no purchase price ($0.0). Following the grant, the reporting person beneficially owned 48,515 shares. The RSUs vest 33.33% on August 15, 2026, with the remaining 66.67% vesting in equal quarterly installments over the subsequent two years on each February 15, May 15, August 15 and November 15, contingent on continuous service through each vesting date.
Insider Form 4 summary: Leslie Trigg, Chair and CEO of Outset Medical, sold 904 shares of common stock on 08/15/2025 at $12.88 per share to satisfy tax withholding related to the vesting of 1,769 restricted stock units granted on January 6, 2023 and January 12, 2024. The sale is described as a "sell to cover" to meet withholding obligations and not a discretionary trade. After the transaction, Trigg beneficially owns 122,328 shares directly and 42,250 indirectly (41,666 via the Trigg 2002 Rev Trust and 584 via the Trigg Family Trust).